Manufacturing Intelligence — July 15, 2026
|
Johnson & Johnson is shedding manufacturing sites in a $750 million restructuring while pouring $55 billion into U.S. production, a build-and-prune approach that shows large-cap pharma reshoring and rationalizing at once, with CDMO dealmaking and AI-integrated manufacturing alliances redrawing the contract landscape.
Today’s top developments:
|
What to Watch
- FDA hub-and-spoke comment period — Watch for the opening of the public comment period on the FDA’s proposed distributed manufacturing registration rule; PhRMA, BIO, and ISPE are likely to press on how quality-system oversight is split between hub and spoke sites and how the rule meshes with existing site-change supplement requirements.
- Hengrui–Elevar reinspection — After a third Complete Response Letter tied to a Form 483 at a rivoceranib plant, a cGMP reinspection and preapproval inspection could gate the next resubmission of the rivoceranib–camrelizumab combination in hepatocellular carcinoma.
- AstraZeneca–Dizal technology transfer — Integrating Zegfrovy’s approved manufacturing process and clearing the CMC site-change supplements that can take 12–24 months will determine how quickly AstraZeneca can leverage the up-to-$1.5B licensed lung cancer asset.
- Biosimilar manufacturing capacity — The OneSource–Formycon mandate and a crowded post-Stelara biosimilar field point to accelerating demand for specialized biologics CMO capacity; watch for further CDMO partnerships and capacity announcements as entrants ramp toward commercial scale.
This brief highlights the edition’s top stories. Read the full July 15, 2026 edition → for all stories and analysis — or browse the Manufacturing Intelligence archive.